EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling

Sun-Ae Park iD, Hee Jung Kim iD, Lee Kyung Kim iD, Hae-Ri Lee iD, Bo-Kyung Jung iD, Ji Hyeon Kim iD, Myung Jin Kim iD, Tae Gwon Oh iD, Hee Eun Kang iD, Kye Jung Shin iD, Jae Hong Seo iD, Tae-Hwe Heo iD

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.70142 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Sun-Ae Park und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma L…. Hauptthemen laut MEDLINE: STAT3 Transcription Factor, Ovarian Neoplasms, Cytokine Receptor gp130, Interleukin-6. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Commercialisation Promotion Agency for R&D Outcomes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Dysregulation of the IL‐6/glycoprotein 130(gp130)/STAT3 signalling axis is implicated in several human diseases, particularly cancer. Notably, gp130, a single transducer of this signalling axis, is a target for ovarian cancer treatment. However, data regarding small‐molecule inhibitors of gp130 are lacking. Therefore, we aimed to identify a 3‐(1,3‐diarylallylidene)oxindole derivative that binds gp130 and reveal the anticancer mechanism acting on the IL‐6/gp130/STAT3 pathway in ovarian cancer. Experimental Approach We synthesised 24 derivatives based on the scaffold of 3‐(1,3‐diarylallylidene)oxindole, and derivatives that inhibit IL‐6 signalling were selected using HEK‐Blue™ IL‐6 cells. The binding of derivatives to gp130 was assessed using surface plasmon resonance. IA‐0130, with a strong gp130‐binding ability, was selected to observe its effect on the migration, invasion, cell cycle arrest and apoptosis of ovarian cancer cells in comparison to bazedoxifene, a known gp130‐binding derivative. Additionally, we examined the mechanism underlying the tumour suppressive effect of IA‐0130 in vivo. Key Results We found that IA‐0130 inhibited gp130/STAT3 phosphorylation in a concentration‐dependent manner in ovarian cancer cell line and also in ovarian cancer‐resistant cell line. By suppressing the expression of downstream target genes, IA‐0130 inhibited cancer cell growth, metastasis, and invasion and induced apoptosis, exhibiting anticancer effects. In a mouse xenograft model of human ovarian cancer, oral administration of IA‐0130 significantly delayed tumour growth. Conclusions and Implications IA‐0130 inhibits tumour growth, migration and metastasis by inhibiting IL‐6/gp130/STAT3 signalling in ovarian cancer by binding gp130. IA‐0130 holds therapeutic potential for treating ovarian cancer as well as anticancer drug‐resistant ovarian cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

STAT3 Transcription FactorOvarian NeoplasmsCytokine Receptor gp130Interleukin-6OxindolesAntineoplastic AgentsIndolesInterleukin-6 InhibitorsFemaleHumansAnimalsSignal TransductionCell Line, TumorMiceCell ProliferationApoptosisMice, NudeHEK293 CellsCell MovementMice, Inbred BALB C

Stichwörter der Autor:innen

3‐(1,3‐diarylallylidene) oxindolesderivativeglycoprotein 130interleukin‐6ovarian cancersignal transducer and activator of transcription 3

Substanzen

STAT3 Transcription FactorCytokine Receptor gp130Interleukin-6OxindolesAntineoplastic AgentsIndolesInterleukin-6 InhibitorsSTAT3 protein, humanIL6 protein, human

Autor:innen und Institutionen

  • Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for Smart Pharma Leaders, College of Pharmacy, The Catholic University of Korea, Bucheon…
  • College of Pharmacy and Integrated Research Institute of Pharmaceutical Sciences, The Catholic University of Korea, Bucheon, South Korea.
  • Research Institute, ILAb Co., Ltd., Seongnam, South Korea.
  • Integrated Research Institute of Pharmaceutical Sciences, College of Pharmacy, The Catholic University of Korea, Bucheon, South Korea.

ORCID-Profile: Sun-Ae Park, Hee Jung Kim, Lee Kyung Kim, Hae-Ri Lee, Bo-Kyung Jung, Ji Hyeon Kim, Myung Jin Kim, Tae Gwon Oh, Hee Eun Kang, Kye Jung Shin, Jae Hong Seo, Tae-Hwe Heo

Förderung

  • National Research Foundation of Korea
  • Commercialisation Promotion Agency for R&D Outcomes

Zitieren

APA

Park, S. A., Kim, H. J., Kim, L. K., Lee, H. R., Jung, B. K., Kim, J. H., Kim, M. J., Oh, T. G., Kang, H. E., Shin, K. J., Seo, J. H., & Heo, T. H. (2025). IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling. British Journal of Pharmacology. https://doi.org/10.1111/bph.70142

Vancouver

Park SA, Kim HJ, Kim LK, Lee HR, Jung BK, Kim JH, et al. IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling. British Journal of Pharmacology. 2025. doi:10.1111/bph.70142

BibTeX
@article{Park2025,
  author = {Park, Sun-Ae and Kim, Hee Jung and Kim, Lee Kyung and Lee, Hae-Ri and Jung, Bo-Kyung and Kim, Ji Hyeon and Kim, Myung Jin and Oh, Tae Gwon and Kang, Hee Eun and Shin, Kye Jung and Seo, Jae Hong and Heo, Tae-Hwe},
  title = {IA‐0130, a novel 3‐(1,3‐diarylallylidene)oxindole derivative, alleviates ovarian cancer via inhibiting IL‐6/gp130/STAT3 signalling},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.70142}
}
Kostenlos starten →